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Abstract
Vascular endothelial growth factor-A (VEGF-A), dimeric glycoprotein, is a 
potent endothelial cell-specific mitogen which plays a key role in angiogenesis, espe-
cially in response to ischemia. Biomarkers reflect various pathophysiological faces of 
spherical LV transformation that related to myocardial stress due to persisted isch-
emia, fibrosis, and inflammation, and they may be helpful to improve risk stratifica-
tion, more personalized medical approach for creating of individual medical care for 
HF preventing and adjusted treatment after STEMI. VEGF-A decrease ≤172.4 pg./
ml on the 7th day of STEMI allows to prognose after infarction angina after 6-month 
observation (area under curve (AUC) 0.697, with sensitivity 88.9% and specific-
ity 50.9%; 95% CI 0.567–0.807, P = 0.0515). Anxiety and depression 10–14 days 
before MI associated with VEGF-A level decrease (anxiety (Taylor): OR 0.834, 95% 
CІ 0.726–0.959, Р = 0.0107; depression (HADS): OR 0.741, 95% CІ 0.535–1.027, 
Р = 0.0519. Cut-off VEGF-A level ≤201.86 pg./ml on the 7th day of STEMI (AUC 
0.711, sensitivity 85.7% and specificity 57.9%; 95% CІ 0.513–0.908, Р = 0.036) was 
effective for prognosis of dysadaptive left ventricular remodeling in STEMI patients 
after 6-month observation period. These findings may open new approach to stratify 
patients with successful coronary revascularization at risk of HF.
Keywords: vascular endothelial growth factor-A, STEMI, prognostication
1. Introduction
Vascular endothelial growth factor-A (VEGF-A) plays a key role in inducing 
angiogenesis. Angiogenesis is a multifunctional process of new vessels formation 
by gemmation or by cleavage of the already existing ones. There are the following 
successive stages of angiogenesis: (1) vasodilatation; (2) migration with adhesion 
and proliferation of endothelial cells; (3) formation of the vascular wall of a new 
three-layer vascular tube that develops as the circulation restores [1]. The VEGF was 
discovered in 1983 [2] as a factor raising vascular permeability, further evidence 
of a wider range of cytokine activity was obtained. There are 7 representatives of 
the VEGF family—VEGF-A, B, C, D, E, F, the growth factor of the placenta. The 
most common is VEGF-A, which is a homodimeric highly glycosylated protein 
with the molecular weight of 36–46 kDa. VEGF is registered in the heart, lungs, 
kidneys, adrenal glands, liver, spleen, stomach, and expression of the protein grows 
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under the pathology conditions. VEGF-A is represented by homodimeric isoforms 
consisting of 121, 145, 148, 165, 183, 189, 206 amino acid residues, among which the 
essential for the vascular system adequate development is VEGF-165 [3–6].
VEGF-A is produced by endothelial cells, smooth muscle vessels, macrophages, 
cardiac fibroblasts, lymphocytes, polymorphous nuclear cells, megakaryocytes, 
monocytes, platelets. Expression of VEGF-A depends on hypoxia, including 
hypoxia-induced factor, proangiogenic factors (HIF-1, EGF, PDGF, FGF,  
IL-1-beta), angiotensin II, endotoxin, high glucose level, IL-6, IL-8, IL-10, pH of 
the medium, oxygen concentration [4–6]. Its products are enhanced by aggrega-
tion of platelets, stretching of the left ventricle myocardium. VEGF is a proin-
flammatory cytokine, it inhibits the formation of dendritic cells, promotes the 
expression of monocytes, macrophages, leukocytes migration, stimulates adhesive 
molecules, and the activity of CD34 [7].
VEGF-A is a promoter of the collaterals formation in the ischemic myocardium, 
has a positive effect on revascularization through the following mechanisms: 
selective mitogenic effect on endothelial cells, stimulation of vascular endothelial 
cells expression, their proliferation, regeneration, vascular permeability increase, 
vasodilatation by activating NO synthase and prostacyclin, inhibition of apoptosis, 
matrix proteinase products. VEGF has antithrombotic properties due to the activa-
tion of serine proteases, urokinase, plasminogen activator, and the thrombolytic 
enzymes generation. However, VEGF induces the formation of the Willebrand 
factor and thrombogenesis [3, 4, 7].
In coronary artery disease (CAD), the double role of VEGF-A has been deter-
mined: under the conditions of acute or chronic myocardial ischemia, VEGF-A is a 
promoter of the coronary collaterals development, which promotes adequate blood 
circulation, oxygen saturation, cardiomyocyte loss prevention, heart remodeling 
improvement, and ultimately, a positive cardioprotective effect [8–11]. However, 
the negative component of the VEGF-A is its proatherogenic properties [12], which 
are implemented through the protein participation in the inflammatory infiltra-
tion of the atherosclerotic plaque, its neovascularization and destabilization. The 
VEGF expression promotes the process of monocytes migration with subsequent 
transformation into macrophages, the formation of foam cells and atherosclerotic 
tissues. The VEGF stimulates the matrix metalloprotease expression, which causes 
the extracellular matrix dissolution and the endothelium migration into a collagen 
gel with the endothelial tubes formation. The de novo formed vessels contribute to 
the plaque growth, its rupture, and destabilization of the clinical course in coronary 
artery disease [7, 13].
Information on changes in the VEGF-A level with stable CAD compared to the 
healthy group varied from its increase [14–16], to decrease [17] or lack of changes [18]. 
A number of studies have shown a direct correlation between the level of VEGF-A 
growth and the degree of damage to coronary vessels. Kucukardali et al. [16], exam-
ined the relationship in patients with proven CHD between the level of VEGF-A in 
blood plasma and the degree of coronary occlusion and the traditional risk factors. 
Groups with normal coronary angiogram (control), critical coronary injuries 
(with stenosis >70%) and non-critical changes (with stenosis of 40–70%) were 
selected. Logistic regression analysis showed that the VEGF-A level in patients with 
critical coronary sclerosis was significantly higher than in patients with normal 
coronary angiogram and non-critical stenosis. Higher levels of total cholesterol and 
LDL cholesterol in patients with critical stenosis were detected, VEGF-A negative 
correlation with hemoglobin and the positive correlation between VEGF-A and the 
age. No relationship was found between VEGF-A and other cardiac risk factors. 
The authors believe that the VEGF-A level growth in patients with coronary heart 
disease indicates critical coronary sclerosis [16]. Lin et al. [14], showed that the 
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VEGF-A level in patients with total coronary occlusion was higher than in patients 
with partial stenotic injuries, indicating the compensatory role of the VEGF-A in 
angiogenesis. Nakajama et al. [15], in patients with marked coronary atherosclero-
sis, detected increased levels of VEGF-A compared to moderate stenosis or its lack 
thereof. Alber et al. [18], however, did not find correlations between the concentra-
tion of VEGF-A in the blood plasma, the presence, severity and extent of coronary 
vessels injuries. The authors drew attention to the fact that in patients treated with 
statins, the level of VEGF-A was lower, this trend indicates the mechanisms of 
statins’ antiangiogenic effect.
Ramos et al. [17], studied the dynamics of the VEGF-A level after PCI and its 
role as a predictor of major adverse cardiovascular events (MACE). Patients with 
ACS (STEMI, MI without ST segment elevation, unstable angina) and without ACS 
with stable angina pectoris were examined. The content of VEGF-A in the blood 
serum before PCI did not depend on the clinical form and was lower than that in 
the healthy group. The level of VEGF-A grew 1 month after revascularization and 
remained stable during 1 year of observation, reaching the control group’s value. 
The results indicate the positive role of the VEGF-A level growth in the endothelium 
regeneration.
Angiogenesis and the coronary collaterals formation in AMI is of particular 
importance as an adaptation process in response to myocardial hypoxia. An increase 
in collateral circulation limits myocardial ischemia, prevents the spread of necrosis, 
improves the function of the myocardium [8]. The ability of VEGF-A to promote the 
development of collateral circulation has been demonstrated on the MI experimental 
models in animals. The use of VEGF for therapeutic angiogenesis in AMI in experi-
mental animals was performed by intracardiac administration of VEGF-encoding 
genes, use of deproteinized isoforms of DNA (pVEGF 165), adenoviral vectors (Ad 
VEGF 121), etc. As a result, initially, in the perinecrotic zone, in remote areas, and 
then in the MI zone, there was an increase in the number of functioning capillar-
ies, their bulk surface, anastomoses, activation of capillary collateral circulation 
[1, 9], improvement of cardiac micro vessels regeneration, cardiac function [10], 
fibrosis reduction and increasing of the myocardium contractile function [11], which 
ultimately reflects the cardioprotective effects of VEGF-A as a result of angiogenesis 
and endothelial cells proliferation.
In most clinical studies, an increase in the VEGF-A level in AMI compared to 
healthy persons, patients with stable or unstable angina [8, 19–24] was determined. 
At the same time, in works by Ramos et al. [17], the level of VEGF-A in patients 
with CAD was lower than in healthy persons, and its differences between clinical 
forms of coronary heart disease were not found.
The analysis of the factors influencing the VEGF level growth in AMI showed 
the following. The classic cardiovascular risk factors (gender, age, hypertension, 
overweight, diabetes mellitus, smoking, hypercholesterolemia) in patients with 
AMI did not correlate with the VEGF-A level [8, 17, 21, 25], although the VEGF-A 
level in patients with H, DM, high BMI, obesity, HF without MI were different from 
healthy ones.
Comparison of the VEGF-A level in patients with AMI with single- and multi-
vascular coronary sclerosis revealed a lack of cytokine correlation with a heart 
attack-dependent coronary artery [8, 21, 26], simultaneously, Wojakovski et al. 
[24], determined higher values of VEGF-A in the blood serum in patients with MI 
with multi-vessel injuries compared to those with single-vessel ones. No relation-
ship was found between the VEGF level and the heart attack localization [8]. 
Results of the connection between the VEGF and the size of the myocardial injury, 
which were determined by the level of CK, CK-MB cardiomarkers, were ambiguous. 
Kranz et al. [8], Shimokawahara et al. [21] did not find any connection between 
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VEGF-A and CK; Hojo et al. [20], Ogawa et al. [22], showed a positive correlation 
between VEGF-A and CK-MB and suggested an association between the prevalence 
of MI and the increase in the VEGF-A formation.
Several studies were devoted to the dynamics of VEGF-A in the acute phase of 
the MI and the subsequent post-infarction prognosis. The VEGF-A level in AMI 
after PCI peaked on the 7th–14th days [8, 20, 21, 27, 28] and returned to the norm 
for 6 months [28]. According to experimental data, administering of VEGF 124 
before the coronary artery occlusion was accompanied by a pronounced activation 
of the angiogenesis process, collateral circulation in the perinecrotic zone and the 
distant regions of myocardium on the 7th day of the experiment [1]. It is possible to 
assume that a peak increase in the VEGF-A level for 7–10 days of AMI corresponds to 
the beginning of active angiogenesis. Mechanisms of VEGF-A endogenous expres-
sion activation in AMI are associated with response to hypoxia and acute myocardial 
ischemia and are implemented at the molecular level. A number of studies have pro-
vided additional information on the pathogenesis of VEGF-A expression enhance-
ment in AMI. Thus, according to Hojo et al. [20], in patients with AMI, VEGF-A 
level was determined in the blood serum and in mononuclear cells of peripheral 
blood. Its blood serum levels peaked at the 14th day of AMI and correlated positively 
with the CK. There was a slight difference in the VEGF-A level in mononuclear 
cells: it was maximally elevated on the 7th day of AMI, did not correlate with CK, its 
reliably higher values were determined in patients with LVEF—≥40% compared to 
the VEGF group <40%. The authors believe that peripheral blood mononuclear cells 
are an important source of VEGF-A, and if they are mononuclear cells that infiltrate 
myocardium injured by infarction, VEGF-A, locally formed by mononuclear cells, 
promotes endothelial proliferation, the formation of microvessels, recovery of 
the damaged endothelium, healing of the infarcted myocardium, performing an 
important role in improving systolic function after MI [20].
Kranz et al. [8], observed a significant increase in the level of VEGF-A in the 
blood of AMI patients, which was maximally expressed on the 7th–10th days and 
reached the baseline value for 6 months, with unstable angina, the cytokine value 
did not reliably differ from the control. The absence of VEGF-A level differences in 
the blood serum and coronary sinus was detected unexpectedly, i.e. the infracted 
myocardium is not the main source of VEGF-A in the blood stream. The authors 
found a reliable growth in the number of platelets in the dynamics of MI. Platelets 
are an important source of VEGF-A, and the cytokine level growth in AMI can be 
explained by an increase in the number of platelets, and their aggregation enhance-
ment, which leads to the secretion of growth factors from alpha granules.
Korybalska et al. [23], determined a significant increase in the level of VEGF-A 
in the blood serum of STEMI patients compared to healthy individuals. The num-
ber of platelets did not differ between patients with STEMI and healthy persons, 
however, in patients with STEMI, a direct reliable correlation between VEGF-A 
and platelets was found. The cytokine concentration increased immediately after 
retrosternal pain onset in patients with occlusive thrombi, which corresponded to 
the 3–4° by the TIMI scale. The authors believe that the VEGF-A level growth in 
patients with STEMI occurs not only due to ischemia and hypoxia of the myocar-
dium, but can also be formed from activated platelets and characterize patients with 
increased intracoronary thrombosis [23].
Wojakovski et al. [24], studied the correlation between the levels of the VEGF, 
pro- and anti-inflammatory markers, traditional risk factors, the status of sys-
tolic function of the lungs, and the marker of inflammation—high sensitive CRP 
(hsCRP) in patients with AMI and stable angina. The authors found that the level 
of VEGF-A in patients with AMI was reliably higher than in those with stable 
angina, in AMI patients with a multi-vessel injury it was higher than in those with 
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mono-vascular injury, in group with EF <40% and Killip III–IV class in comparison 
with EF >40% and Killip I–II class, with a duration of pain syndrome >6 h compared 
to that of <6 h. Acute myocardial ischemia was associated with a reduction in the 
level of anti-inflammatory cytokine IL-10. Although the authors did not find cor-
relation between VEGF-A and IL-10, they believe that changes of these cytokines 
concentration will help identify persons with high cardiovascular risk. The level 
of hsCRP, a marker, the importance of which was proven in inflammation, had a 
negative correlation with anti-inflammatory cytokine IL-10 and a positive one with 
VEGF-A, which indicates the VEGF-A participation in the immune response to AMI.
Eržen et al. [28], determined a reliable increase in the level of the VEGF in 
patients with MI, on average 20.5 months ago, compared to the control, a reliable 
positive correlation between the VEGF level and the pro-inflammatory IL-6 and 
IL-8 molecules, lack of correlation between VEGF and the atherosclerotic injury 
parameters, although dilatation of the right shoulder artery and the intima-media 
thickness of the common carotid artery in the examined patients were significantly 
weakened. The authors believe that the VEGF-A increase in the stable phase after 
the past MI is a part of inflammatory activity, since VEGF-A in these patients 
stimulates neovascularization, inflammation of the plaque and promotes its desta-
bilization, its level increase may have a negative prognostic value.
An important component in raising the VEGF-A level, angiogenesis enhanc-
ing, cardiac blood flow, myocardial perfusion, oxygen transport, and the entry of 
energy substrates into cardiomyocytes is its effect on the structural and functional 
parameters of the myocardium, followed by adaptive or dysadaptive remodeling. 
Moreover, the VEGF-A expression and its receptors in cardiac fibroblasts and 
non-endothelial cells with properties of fibroblasts that perform tissue growth and 
regeneration assumes cytokine involvement in the process of myocardial remodel-
ing in the ischemia and necrosis zones [29]. With experimental MI in rats, adminis-
tration of VEGF-A-165 and VEGF-B-167 into the myocardium reduced myocardial 
fibrosis and improved its contractile function, viability, and remodeling of the left 
ventricle [11]. Administration of anti-P-selectin-conjugated liposomes containing 
the VEGF to experimental MI rats was accompanied by a 37% reduction in collagen 
deposition in the myocardium, a significant improvement in the pressure of the LV 
filling, with a significant improvement in the cardiac function 4 weeks after the 
MI: LV EDD reduction, growth of the fractional shortening, at the same time, the 
number of anatomical and perfused vessels increased [10, 30, 31]. Injection of  
the collagen-bound VEGF domain resulted in the infarction area reduction, 
improvement of the processes of LV remodeling within 3 months, and 12 months 
later, in the MI zone, mature vasculature and myocardium-like tissues were 
observed. Thus, the protection of cardiomyocytes from apoptosis and involvement 
of precursor cells in the infarction zone occurred [32].
The results of clinical studies on the correlation between VEGF-A and post-
infarction remodeling are ambiguous. Thus, in the AMI patients, the indices of LV 
volumes, determined by ventriculography on the 14th day of AMI, were increased 
in the group with a high peak VEGF-A value compared to the low VEGF-A value 
group, the peak of the VEGF-A plasma level positively correlated with LV EDV 
and LV ESV. These differences were absent in the chronic phase of MI. The authors 
believe that endogenous VEGF-A plays an important role in the dilatation of LV in 
patients with AMI [21]. Soeki et al. [33], referred patients, in whom 3 months after 
the AMI an increase in the EDV-index was more than 5 ml/m2, to the group with 
remodeling; the authors did not find changes in the VEGF level between patients 
with and without remodeling. However, patients with AMI and improvement of 
systolic function, compared to patients without such improvement, had higher 
VEGF-A levels in mononuclear cells of the peripheral blood; the authors believe that 
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VEGF-A, which is formed in mononuclear cells infiltrating the infarcted myocar-
dium, plays an important role in angiogenesis, re-endothelialization, restoration 
of the LV systolic function after the AMI [20]. Devaux et al. [19], determined the 
LV remodeling according to the EDV dynamics in the period between the patient’s 
hospitalization and 6 months after the MI; the first group consisted of patients 
with ΔEDV, which did not undergo significant changes or was decreasing; group 2 
included patients whose ΔEDV was increasing. The level of VEGF-B was 69% 
higher in patients with ΔEDV ≤ 0 than in patients with ΔEDV > 0. The authors 
believe that the low level of VEGF-B in blood with AMI is associated with a high risk 
of LV remodeling and is its predictor.
In accordance with the spectrum of the VEGF biological cardiovascular effects, 
a number of studies are devoted to the role of cytokine for the long-term prognosis in 
patients with MI. The contradictory results were obtained. Thus, Heeschen et al. [34], 
determined the level of VEGF-A in plasma of 1090 patients with ACS 8.7 h after the 
onset of the event. The frequency of major cardiovascular complications during the 
6 months of observation was high in patients with the initially increased VEGF-A 
level. But other studies have obtained evidence that it is the decrease in the VEGF-A 
level which is an independent prognostic factor of recurrent cardiovascular events 
in other studies. Thus, Niu et al. [25], determined the VEGF-A level on the 7th day 
after MI, groups with low and high (less than or greater than 190 ng/ml) median 
VEGF-A levels. Repeated examinations were carried out every 2 months dur-
ing the year; MACE, which included cardiovascular death, heart failure, severe 
arrhythmias, cardiogenic shock and post-infarction angina, were recorded. Within 
6 months, the MACE frequency in the VEGF-A high-level group was significantly 
lower than in the low-cytokine group. Accordingly, the VEGF-A concentration 
in the group of patients without MACE was significantly higher than that in the 
MACE group.
Multivariant regression analysis showed that the decrease of the VEGF-A level is 
an independent MACE risk factor, its high value on the 7th day after AMI determines a 
positive long-term prognosis. Matsudaira et al. [27], examined 879 patients with AMI 
after successful PCI within the framework of a prospective, multicenter NAMIS study 
(Nagoya Acute Myocardial Infarction Study). According to VEGF-A level terciles, 
which was determined on the 7th day of AMI, 3 groups were formed, in which within 
6 months of observation the major unfavorable cardiac and cerebral events were 
determined: cardiac death, repeated ACS, hospitalization for heart failure, strokes. 
Compared to the “medium” tercile, patients with the “low” tercile had a much higher 
risk of MACE. The authors believe that the low of VEGF-A level on the 7th day after 
AMI is associated with a significant increase in the MACE risk for 6 months.
Unlike the previous authors, Ramos et al. [17], determined that the level 
of VEGF-A in patients with AMI was lower than that of healthy individuals at 
admission, it was getting increased within 1 month term and remained steadily 
increased up to 1 year of observation. But in this study, it was shown that a 
decrease in the VEGF-A level < 40.8 pg./ml contributed to an increased risk of 
MACE for 5 years. The obtained results indicated the positive role of VEGF-A in 
the cardiovascular circulation restoration and confirmed its prognostic impor-
tance. In studies of Teplyakov et al. [35], the degree of ischemic genesis cardiac 
failure progression, most of the examined were postinfarction patients, there was 
a decrease in the VEGF-A level, and the initial low VEGF-A level characterized the 
unfavorable CHF course.
It is known that psychological stress is involved in the development and progres-
sion of cardiovascular disease. Thus, in an INTERHEART study performed in 52 
world countries, anxiety and depression ranked third among the MI risk factors [36]. 
In Surtees et al. [37], within the 8.5 years period of observation, patients with a 
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“major” depression were by 2.7 times more likely to die from the coronary heart 
disease. Findings from this large prospective cohort study suggest that increased 
psychological distress is associated with elevated stroke risk. Episodic major depres-
sive disorder was not associated with incident stroke in this study. Doering et al. 
[38], demonstrated that the presence of anxiety and depression was the predictor of 
the overall death-rate in patients with coronary artery disease. Versteeg et al. [39],  
showed that depression was independently associated with an increased risk 
of the overall death-rate for 5 years in patients with coronary artery disease. In 
the study by Beach et al. [40], the high level of depression by the Patient Health 
Questionaire-9 (PHQ-9) was reliably associated with re-hospitalization after 
6 months in patients with acute coronary syndrome, heart failure, or arrhythmia.
Mechanisms to be associated with anxiety-depressive disorders (ADD) and 
cardiovascular diseases are complex and take into account both behavioral and 
physiological factors: smoking, lifestyle underactivity, obesity, as well as increased 
platelet aggregation, arterial pressure, reduced insulin sensitivity and disordered 
endothelial function [41, 42].
In recent years, the evidence base for participation of VEGF-A in the cerebrovascu-
lar disease pathogenesis, including ADD, is growing. VEGF-A is known to be involved 
in such processes in the central nervous system as the ontogenetic development of the 
nervous system, which includes the processes of migration, differentiation,  
synaptogenesis, myelination, neuroprotection, stimulation of neurogenesis in 
adulthood, post-ischemic restoration of cerebral and vessel tissues, stimulation of 
memory formation mechanisms. VEGF-A participates in all phases of neuro-and 
angiogenesis: formation of blood vessels de-novo from mesenchymal stem cells, 
formation of new capillaries, expansion of arteriolar anastomoses, and also demon-
strates direct neurotrophic and neuroprotective properties. Thus, the role of VEGF 
in the pathogenesis of cerebrovascular pathology, including anxiety-depressive 
disorders, is to combine angiotropic and neurotropic activity [43].
An increase in the VEGF-A level in patients with major depression was observed 
[44–48]; the correlation between depression and VEGF-A is confirmed by the 
fact that cytokine stimulates neurogenesis caused by antidepressants [49, 50]. In 
patients with coronary heart disease, higher levels of VEGF-A, CRP, IL-6 gene 
expression and cortisol level reduction were detected, indicating an increase in 
immune-mediated activity [51].
It should be noted that in these works, patients with major depression were 
somatically healthy, or patients with coronary artery disease were with a stable 
course. However, in acute experimental ischemia, psychological stress was associ-
ated with a decrease in the VEGF-A and its signaling molecules (P44/P42, MAPK, 
Akt) expression, violation of neurovascularization at the macro- and microvascular 
levels, which the authors associate with the oxidative stress activation in the isch-
emic tissue [52].
The aim of our research was investigation of association between VEGF-A level 
in STEMI patients with TIMI III and development of repeated coronary events and 
adverse remodeling within 6-month follow-up and determination of the factors 
influencing this relationship.
2. Material and methods
2.1 Patients
Sixty-two patients with STEMI, 51 (82.3%) male and 11 (17.7%) female, at the 
average age (58.63 ± 8.90) years with acute STEMI during 2–12 h of symptoms onset 
Vascular Access Surgery - Tips and Tricks
8
in a given period between 2016 and 2017. STEMI was diagnosed according to ECS 
Guidelines [53]. Inclusion criteria were: confirmed STEMI, age >18 years old, and 
lack of contraindication to PCI. Non-inclusion criteria were previous myocardial 
infarction, established chronic HFrEF, HFmrEF and HFpEF, known malignancy, 
severe comorbidities (anemia, chronic obstructive lung disease, bronchial asthma, 
liver cirrhosis, chronic kidney disease, valvular heart disease, bleeding), inability 
to understand of written informed consent. Control group consisted of 20 per-
sons comparable of age and sex. Patients were hospitalized to the Department of 
prevention and treatment of emergency conditions of Government institution 
“L.T. Malaya Therapy National Institute of the National Academy of medical science 
of Ukraine” after selective coronaroangiography (SCAG) with stenting of infarct-
related artery, were performed in the Institute of general and emergency surgery 
n.a. V.T. Zaitsev. Repeated observation performed after 6 month.
Research was performed due to Helsinki Declaration, the protocol was approved 
by local ethics committee of GI “National Institute of therapy n.a. L.T.Malaya 
NAMS Ukraine” (protocol No. 8, 29.08.2016). Informed consent was obtained from 
each patient.
Conventional coronary angiography was performed using Digital X-Ray system 
“Integris Allura” (Philips Healthcare, Best, The Netherlands) and managed by 
radial or femoral vascular access. Coronary arteries were visualized with two-
to-three orthogonal projections. In this study the contrast “Ultravist-370” (Baier 
Pharma GmbH, Germany) and automatic contrast injector were used. Primary 
PCI with bare-metal stent (COMMANDER, “Alvimedica”, Turkey) implantation 
was performed in 36 patients and 26 patients were previously treated with primary 
thrombolysis (tenecteplase, alteplase) before admission with followed PCI dur-
ing 6–12 h after initial STEMI confirmation. Thrombolytic therapy performed by 
tenecteplase, which dosing was calculated depending on patients weight and was 
no more than 50 mg or alteplase, or tenecteplase—100 mg. All the patients intook 
medical therapy in accordance to existing recommendations.
Repeated coronary events (after infarction angina) during 6-month observa-
tion period were estimated and diagnosed in 9 (14.5%) patients. Left ventricular 
remodeling as an end point in 6 months after STEMI were assessed too: adverse 
remodeling was in 29 patients, adaptive—in 33.
2.2 Methods
SYNTAX score (SS) was used to assess the severity of coronary atherosclerotic 
lesions and was calculated for all PCI-patients by experienced interventional 
cardiologist. SS was determined for all coronary lesions >50% diameter stenosis in 
a vessel >1.5 mm based on SS calculator (www.syntaxscore.com). All the patients 
were divided by the SS level on 3 subgroups—high SS > 32–2 patients, average SS 
22 < n ≤ 32–17, low SS ≤ 22–32.
Echo-CG was performed on “Aplio 500 TUS-A500”, Toshiba, with usage of sen-
sor with ultrasound frequency of 3.5 MHz during first 24 h from hospitalization. Left 
ventricular end diastolic volume (LV EDV), left ventricular end systolic volume (LV 
ESV), left ventricular end diastolic and end systolic diameters (LV EDD, LV ESD),  
left ventricular myocardial mass (LVMM), left ventricular ejection fraction (LVEF), 
diastolic dysfunction—maximal rate of early diastolic filling E (m/s), maximal rate 
of left atrium diastolic rate A (m/s), their ratio—E/A were estimated. Repeated 
observation was done after 6-month period. VEGF-A level was assessed on the 7th 
day of STEMI. Late adverse cardiac remodeling was defined as increased LVEDV 
(>10% from baseline) and/or LVESV (>10% from baseline) for 6 months after 
acute STEMI managed by PCI.
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Hypercholesterolemia (HCE) was diagnosed if total cholesterol (TC) level was 
above 5.2 mmol/l, and/or low density lipoprotein cholesterol (LDL) level was above 
3.0 mmol/l, and/or level of triglycerides (ТG) was above 1.7 mmol/l according to 
with European Cardiology Society dyslipidemia guideline, 2016. Hypertension 
was diagnosed if systolic blood pressure (SBP) was >140 mm Hg, and/or diastolic 
blood pressure (DBP) >90 mm Hg according to European guideline on diagnostics 
and treatment of arterial hypertension, 2018. Type 2 diabetes mellitus determined 
according to new ADA statement [54].
The level of anxiety during 10–14 days before STEMI estimated due to Taylor 
questionnaire. High level of anxiety was consistent with less or equal 14 balls, high 
level—more than 14 balls. Together with Taylor questionnaire, Heart Anxiety and 
Depression Scale (HADS) was used to diagnose anxiety and depression: 0–7 balls—
low level, 8–10—borderline, 11–21—high.
Troponin I (Tn I) level measuring performed with chemo luminescent immu-
noassay (Humalyzer 2000, Mannheim, Germany). The TnI level average was 
0.5–50 ng/ml. Total creatine kinase (CK) and CK MB-fraction (CK-MB) were 
analyzed using immunoinhibition method on quantitative immunoassay analyzer 
Humalyzer 2000 (Mannheim, Germany) according to the manufacturers’ recom-
mendations. Total cholesterol (TC), low density lipoprotein (LDL) cholesterol, 
high density lipoprotein (HDL) cholesterol and triglycerides (TG) were measured 
direct enzymatic method (Roche P800 analyzer, Basel, Switzerland). The intra-
assay and inter-assay coefficients of variation were <5%. Fasting glucose level was 
measured by a double-antibody sandwich immunoassay (Elecsys 1010 analyzer, 
F. Hoffmann-La Roche Diagnostics, Mannheim, Germany). The intra-assay and 
inter-assay coefficients of variation were <5%.
Blood research were done at baseline. VEGF-A level determined by enzyme-
linked immunosorbent assay with reactives of IBL INTERNATIONAL GMBH, 
Germany (standard concentrations diapason 0.0–1000 pg./ml, serum control: 
low—100–200, high—600–1200 pg./ml) in the laboratory of immune-chemical 
and molecular-genetic researches of GI “National Institute of therapy n.a. 
L.T. Malaya NAMS Ukraine”. Serum VEGF-A level measured in the 7th day of 
STEMI: in the main group it was equal 160.33 [83.82–299.62] pg./ml, in the control 
group—112.30 [75.45–164.65] pg./ml (Р = 0.05).
2.3 Statistical analyses
Statistical data processing was performed with programs Statistica 8.0 (Stat Soft 
Inc., USA), median (Ме) with upper (UQ ) and low quartiles (LQ ). Continuous 
variables are presented as mean ± standard deviation when normally distributed, 
or median and interquartile range if otherwise. Mann-Whitney U-criterion and 
Wald-Wolfowitz χ2- criterion were used for intergroup differences. For all types 
of analysis, all differences were considered statistically significant with P < 0.05. 
Univariate and multivariate logistic statistical analyses were used. The group with 
repeated coronary events pointed as 1, without events—0, cut-off point with 
VEGF-A were found.
3. Results
The first group with repeated coronary events (after infarction angina) rep-
resented 9 patients (14.5%), the second group consisted from 53 patients without 
angina to 6 months after STEMI. Cardiovascular risk factors [sex, age, H, DM, 
HCE, complicated heredity, anxiety-depressive disorders (ADD)] showed the 
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absence of reliable differences between patients of group 1 and 2. VEGF-A level was 
significantly less in patients from group 1:83.82 [49.14–162.26] pg./ml versus 194.10 
[102.54–327.30] pg./ml accordantly, Р = 0.049.
ROC-analysis was performed to find VEGF-A level which prognoses repeated 
coronary events after 6-month observation after STEMI. Cut-off VEGF-A 
level ≤ 172.4 pg./ml on the 7th day of index event (area under curve (AUC) 0.697, 
with sensitivity 88.9% and specificity 50.9%; 95% CІ 0.567–0.807, Р = 0.0515) was 
effective for differentiation STEMI patients from those without and with unfavor-
able prognosis of repeated coronary event—after infarction angina (Figure 1).
To identify factors influenced on VEGF-A level, univariate and multivariate 
logistic analysis were performed. In patients with STEMI was revealed association 
between anxiety and depression levels increase and VEGF-A level decrease (anxiety 
(Taylor): OR 0.834, 95% CІ 0.726–0.959, Р = 0.0107; depression (HADS): OR 0.741, 
95% CІ 0.535–1.027, Р = 0.0519.
ROC-analysis for prognostication of dysadaptive left ventricular remodeling was 
used. Cut-off VEGF-A level ≤ 201.86 pg./ml on the 7th day of STEMI (area under 
curve (AUC) 0.711, with sensitivity 85.7% and specificity 57.9%; 95% CІ 0.513–0.908, 
Р = 0.036) was effective for unfavorable prognosis of dysadaptive left ventricular 
remodeling of STEMI patients after 6-month observation period (Figure 2).
As a result of our research, we revealed than anxiety and depression 10–14 days 
before MI associated with VEGF-A level decrease (anxiety (Taylor): OR 0.834, 95% 
CІ 0.726–0.959, Р = 0.0107; depression (HADS): OR 0.741, 95% CІ 0.535–1.027, 
Р = 0.0519. VEGF-A decrease ≤172.4 pg./ml on the 7th day of STEMI allows to prognose 
Figure 1. 
Cut-off VEGF-A level ≤ 172.4 pg./ml on the 7th day of STEMI (area under curve (AUC) 0.697, with 
sensitivity 88.9% and specificity 50.9%; 95% CІ 0.567–0.807, Р = 0.0515) was effective for differentiation STEMI 
patients from those without and with unfavorable prognosis of repeated coronary event (after infarction angina 
after 6-month observation).
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repeated coronary events (after infarction angina) after 6-month observation with  
sensitivity of 88.9% and specificity 50.9%. Cut-off VEGF-A level ≤ 201.86 pg./ml on the 
7th day of STEMI (area under curve (AUC) 0.711, with sensitivity 85.7% and specificity  
57.9%; 95% CІ 0.513–0.908, Р = 0.036) was effective for prognosis of dysadaptive left 
ventricular remodeling in STEMI patients after 6-month observation period.
4. Conclusion
We have shown that the levels of VEGF-A measured in acute STEMI patients 
managed by PCI could predict late adverse LV remodeling and after infarction 
angina. These findings may open new approach to stratify patients with successful 
coronary revascularization at risk of HF.
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